If you have been reading about storage stability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
=== Mechanism of action === Enoxaparin binds to and activates antithrombin (a circulating anticoagulant) to form a complex that irreversibly inactivates clotting factor Xa. It has less activity against factor IIa (thrombin) compared to unfractionated heparin (UFH) due to its low molecular weight.
Natural uranium is made weapons-grade through isotopic enrichment. Initially only about 0.7% of it is fissile U-235, with the rest being almost entirely uranium-238 (U-238). They are separated by their differing masses. Highly enriched uranium is considered weapons-grade when it has been enriched to about 90% U-235. U-233 is produced from thorium-232 by neutron capture. The U-233 produced thus does not require enrichment and can be relatively easily chemically separated from residual Th-232. It is therefore regulated as a special nuclear material only by the total amount present. U-233 may be intentionally down-blended with U-238 to remove proliferation concerns. While U-233 would thus seem ideal for weaponization, a significant obstacle to that goal is the co-production of trace amounts of uranium-232 due to side-reactions. U-232 hazards, a result of its highly radioactive decay products such as thallium-208, are significant even at 5 parts per million. Implosion nuclear weapons require U-232 levels below 50 PPM (above which the U-233 is considered "low grade"; cf. "Standard weapon grade plutonium requires a Pu-240 content of no more than 6.5%." which is 65,000 PPM, and the analogous Pu-238 was produced in levels of 0.5% (5000 PPM) or less). Gun-type fission weapons would require low U-232 levels and low levels of light impurities on the order of 1 PPM.
=== Side effects === Sulfonylureas – as opposed to metformin, the thiazolidinediones, pramlintide and other newer treatments – may induce hypoglycemia as a result of excesses in insulin production and release. Hypoglycemia appears to happen more often with sulfonylureas than compared to other treatments. This typically occurs if the dose is too high, and the patient is fasting. Some people attempt to change eating habits to prevent this, however it can be counterproductive. Like insulin, sulfonylureas can induce weight gain, mainly as a result of their effect to increase insulin levels and thus use of glucose and other metabolic fuels. Other side-effects are: gastrointestinal upset, headache and hypersensitivity reactions. Skin reactions and dark-colored urine, which indicates a liver injury, are other side effects that have been observed. The safety of sulfonylurea therapy in pregnancy is unestablished. Prolonged hypoglycemia (4 to 10 days) has been reported in children borne to mothers taking sulfonylureas at the time of delivery. Impairment of liver or kidney function increase the risk of hypoglycemia, and are contraindications. Since other antidiabetic drugs cannot be used either under these circumstances, insulin therapy is typically recommended during pregnancy and in liver and kidney failure, although some of the newer agents offer potentially better options. A 2011 Cochrane review found evidence that treatment of LADA using sulfonylureas lead to earlier insulin dependence in approximately 30% of cases.
=== Dynamics of surfactants at interfaces === The dynamics of surfactant adsorption is of great importance for practical applications such as in foaming, emulsifying or coating processes, where bubbles or drops are rapidly generated and need to be stabilized. The dynamics of absorption depend on the diffusion coefficient of the surfactant. As the interface is created, the adsorption is limited by the diffusion of the surfactant to the interface. In some cases, there can exist an energetic barrier to adsorption or desorption of the surfactant. If such a barrier limits the adsorption rate, the dynamics are said to be ‘kinetically limited'. Such energy barriers can be due to steric or electrostatic repulsions. The surface rheology of surfactant layers, including the elasticity and viscosity of the layer, play an important role in the stability of foams and emulsions.
Sources: en.wikipedia.org
== Early life == Louis Szathmary was born on June 2, 1919, on a train heading from Transylvania to Budapest as his parents fled the post World War I Hungarian–Romanian War. He earned his master's degree in journalism and doctorate in psychology from the University of Budapest before being drafted into the Hungarian army to serve in World War II. Szathmary originally served as a psychologist to Hungarian Army men, before transferring positions to Army private, where he wrote manuals, including one for cooking. Subsequently, he enrolled in a Hungarian chef's school and took an advanced course.
== Modelling the Basal Rate == Most adult diabetics (over the age of 21) will have a fairly constant ratio of bolus:basal of 60%:40%, where 60% of all insulin intake in a single 24-hour period will be attributed to meals (bolus) and 40% should then be attributed to the basal rate. This ratio will fluctuate from person to person depending on their size, activity level, and caloric intake as well but is a good baseline for determining the correct basal rate for an adult diabetic. Thus, the basal rate could theoretically be set based on an averaged bolus insulin intake of several days. Averaging the total bolus, and then dividing this number by 36 would then give the required hourly basal rate intake for any individual with a 60:40 ratio established.
=== Bioanalysis === Biomolecules in samples such as galactose can be quantified using oxygen detection method, since one equivalent consumption of oxygen corresponds to one equivalent primary hydroxyl group oxidized. The formation of hydrogen peroxide during substrate oxidation can also be used for colorimetric detection of galactose using dyes that are oxidized by hydrogen peroxide. Because carbohydrates can normally have primary hydroxyl groups, galactose oxidase can be used to modify cell surface glycoproteins to achieve cell labelling.
=== Trial === When the case reached the Old Bailey in September 1994, Mr Justice Ognall ruled that the police had shown "excessive zeal" and had tried to incriminate Stagg by "deceptive conduct of the grossest kind". He excluded all the entrapment evidence on the grounds that Stagg's descriptions of the murder were not nearly as close to the reality as the police had maintained. With no other evidence to present, the prosecution withdrew its case and Stagg was acquitted. Keith Pedder, the case's lead detective, received heavy public criticism. Even after Stagg was (rightfully as it later turned out) cleared of the murder of Nickell, Pedder continued over subsequent years to promote his theory that Stagg was guilty. He told an ITV Real Crime documentary in 2001:
Shimeji (Japanese: シメジ, 占地 or 湿地) is a group of edible mushrooms native to East Asia, but also found in northern Europe. Hon-shimeji (Lyophyllum shimeji) is a mycorrhizal fungus and difficult to cultivate. Other species are saprotrophs, and buna-shimeji (Hypsizygus tessulatus) is now widely cultivated. Shimeji is rich in umami-tasting compounds such as guanylic acid, glutamic acid, and aspartic acid.
Sources: en.wikipedia.org
Key State Department personnel grew increasingly frustrated with and suspicious of the Soviets as the war drew to a close. Averell Harriman, US Ambassador in Moscow, once a "confirmed optimist" regarding US–Soviet relations, was disillusioned by what he saw as the Soviet betrayal of the 1944 Warsaw Uprising as well as by violations of the February 1945 Yalta Agreement concerning Poland. Harriman would later have a significant influence in forming Truman's views on the Soviet Union. In February 1946, the US State Department asked George F. Kennan, then at the US Embassy in Moscow, why the Russians opposed the creation of the World Bank and the International Monetary Fund. He responded with a wide-ranging analysis of Russian policy now called the Long Telegram:
=== Afghanistan === Saffron has a long history in Afghanistan, with cultivation believed to date back to before Alexander the Great's conquest of the Persian Empire. Due to prolonged droughts, conflict, and shifts in agricultural focus, saffron farming declined for centuries. Cultivation resumed in the early 2000s as an alternative to opium poppy farming, supported by international organizations and the Afghan government. According to Afghanistan's Ministry of Agriculture, Irrigation, and Livestock, production increased from 20 metric tons in 2022 to 46 metric tons in 2024. Key export markets include India, Europe, and the United States, where Afghan saffron is prized for its high quality. Saffron cultivation contributes significantly to Afghanistan's economy, supporting thousands of farmers, particularly women. Over 80% of the saffron workforce consists of women, who primarily handle harvesting and processing. The sector has provided employment opportunities for over 40,000 people, playing a role in agricultural sustainability and rural development. Afghan saffron is known for its deep red color, strong aroma, and high crocin content, a compound that determines color intensity. It has been ranked among the highest quality saffron varieties in recent years with a 310 Crocin color quality based on ISO 3632.2 standards.
=== Therapeutic potential === Further research into myostatin and the myostatin gene may lead to therapies for muscular dystrophy. The idea is to introduce substances that block myostatin. A monoclonal antibody specific to myostatin increases muscle mass in mice and monkeys. A two-week treatment of normal mice with soluble activin type IIB receptor, a molecule that is normally attached to cells and binds to myostatin, leads to a significantly increased muscle mass (up to 60%). It is thought that binding of myostatin to the soluble activin receptor prevents it from interacting with the cell-bound receptors. In September 2020 scientists reported that suppressing activin type 2 receptors-signalling proteins myostatin and activin A via activin A/myostatin inhibitor ACVR2B – tested preliminarily in humans in the form of ACE-031 in the early 2010s – can protect against both muscle and bone loss in mice. The mice were sent to the International Space Station and could largely maintain their muscle weights – about twice those of wild type due to genetic engineering for targeted deletion of the myostatin gene – under microgravity. Treating progeric mice with soluble activin receptor type IIB before the onset of premature ageing signs appear to protects against muscle loss and delay age related signs in other organs. It remains unclear as to whether long-term treatment of muscular dystrophy with myostatin inhibitors is beneficial, as the depletion of muscle stem cells could worsen the disease later on. As of 2012, no myostatin-inhibiting drugs for humans are on the market.
Palestinian militancy has been the main focus of the IDF ever since, especially during the First and Second Intifadas, Operation Defensive Shield, the Gaza War, Operation Pillar of Defense, and Operation Protective Edge, causing the IDF to change many of its values and publish the IDF Spirit. The Lebanese Shia organization Hezbollah has also been a growing threat, against which the IDF fought an asymmetric conflict between 1982 and 2000, as well as a full-scale war in 2006.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.